Physician profile
Cheri Blacksten
NPI 1124254586
$9,047.11
in general payments reported to CMS, 2019-2025
37 companies · $2,631 in 2025
The $2,631 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $640 · 2020: $1,310 · 2021: $1,448 · 2022: $1,061 · 2023: $1,154 · 2024: $802 · 2025: $2,631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,457 · Consulting Fee: $2,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,457.35 |
| Consulting Fee | $2,130.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,332.14 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $977.83 | 2019-2025 | Breztri, Farxiga, Fasenra |
| Abbvie INC. | $670.93 | 2020-2024 | Ubrelvy, Vraylar, Qulipta |
| Lilly USA, LLC | $669.72 | 2019-2024 | Emgality, Jardiance, Mounjaro |
| Pfizer INC. | $421.05 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $297.90 | 2019-2022 | |
| Allergan, INC. | $270.22 | 2019-2020 | |
| Glaxosmithkline, LLC. | $257.32 | 2019-2023 | Nucala |
| Nestle Healthcare Nutrition INC. | $240.32 | 2020-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.44 | 2020-2024 | Jardiance |
| Amgen INC. | $202.90 | 2020-2024 | Otezla, Repatha, Enbrel |
| Amarin Pharma, INC. | $193.18 | 2020-2021 | |
| Daiichi Sankyo INC. | $137.06 | 2022-2023 | Injectafer |
| Exact Sciences Corporation | $123.04 | 2023-2025 | Cologuard Collection Kit |
| Organon LLC | $122.67 | 2021-2023 | Nexplanon |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheri Blacksten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.